Table 4.
Unadjusted healthcare costs associated with COPD exacerbations in patients treated with fluticasone propionate/salmeterol versus salmeterol: pooled clinical trials data
| Cost component |
Cost in US dollars |
||
|---|---|---|---|
| FSC group, mean/median (SD) (N = 776) | SAL group, mean/median (SD) (N = 778) | Mean cost difference (FSC–SAL) | |
| Exacerbation-related costs | |||
| Total cost, any exacerbation (mild, moderate, severe) | 1127/114 (2906) | 1351/116 (3225) | −224a |
| Total cost, moderate exacerbation | 243/114 (352) | 301/116 (436) | −58a |
| UC visit | 3.34/0 (21) | 2.22/0 (16) | 1.12 |
| ED visit | 75/0 (225) | 107/0 (314) | −32 |
| Office visits | 73/0 (118) | 89/0 (145) | −16 |
| Antibiotic | 90/0 (117) | 101/0 (128) | −10 |
| Oral corticosteroid | 1.73/0 (3) | 2.21/0 (3) | −0.48a |
| Total cost, severe exacerbation | 884/0 (2683) | 1050/0 (2938) | −166 |
| Hospitalization | 613/0 (2113) | 859/0 (2532) | −246 |
| ICU | 271/0 (1813) | 191/0 (1526) | 80 |
| Study medication costs | 1651/2002 (643) | 962/1307 (501) | 689a |
| Total cost | 2778/2024 (2919) | 2313/1328 (3224) | 465a |
| Total annualized cost | 4291/2101 (11,027) | 4596/1469 (13,042) | −304a |
Notes:
a
P < 0.05, Wilcoxon rank sum test.
Abbreviations: FSC, fluticasone propionate/salmeterol 250 μg/50 μg; SAL, salmeterol 50 μg; UC, urgent care; ER, emergency department; ICU, intensive care unit; COPD, chronic obstructive pulmonary disease.